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ABSTRACT
Colonoscopy is a widely performed procedure with
procedural volumes increasing annually throughout the
world. Many procedures are now performed as part of
colorectal cancer screening programmes. Colonoscopy
should be of high quality and measures of this quality
should be evidence based. New UK key performance
indicators and quality assurance standards have been
developed by a working group with consensus
agreement on each standard reached. This paper reviews
the scientific basis for each of the quality measures
published in the UK standards.
INTRODUCTION
Colonoscopy is a widely performed procedure for
patients with lower GI symptoms and is an integral
part of all colorectal cancer (CRC) screening pro-
grammes, either primarily or secondarily following
positive stool tests or other colonic imaging. There
is evidence from randomised trials that faecal
occult blood tests (guaiac faecal occult blood
testing (FOBT)) and sigmoidoscopy1–4 reduce CRC
mortality in screening, but there is currently no evi-
dence from randomised trials for screening colon-
oscopy.5–7 Results from trials are expected in the
2020s.
It is fundamentally important that colonoscopy
procedures are of the highest possible quality and
that measures of quality are based upon evidence.
Widely used quality measures include caecal intub-
ation and adenoma detection rates (ADR) and these
should be evaluated alongside other measures of
quality. New UK key performance indicators (KPI)
and quality assurance (QA) standards for colonos-
copy have been developed by the British Society
of Gastroenterology (BSG), the Joint Advisory
Group for GI Endoscopy and the Association of
Coloproctology of Great Britain and Ireland and
are published in this edition of Gut.8 The evidence
presented in this review paper is taken from the
development of these guidelines and from data
review performed for the recently published
German guidelines on quality standards in GI
endoscopy.9 While colonoscopy is crucial in the
detection and prevention of CRC, this will only be
the case if procedures are performed to high stan-
dards. In the UK, a 2012 national audit10 demon-
strated a significant improvement in colonoscopy
completion rates when compared with a previous
1999 audit, it also showed that wide variation still
existed between centres and endoscopists.10 11
While colonoscopy can detect CRC and prevent it
by removal of adenomas,12 it can also lead to
serious complications and quality measures should
ensure that these are minimised.13–16 Additionally,
poor quality colonoscopy is associated with
increased rates of interval cancers.17 18 A major
challenge is to deliver high quality colonoscopy in
the setting of ever-increasing demand and activity.
England has seen a 20% increase in colonoscopy
activity over the last 5 years with 360 000 proce-
dures performed annually.19 In the USA, 14 million
colonoscopies are performed per year,20 with a sig-
nificant percentage being primary screening colon-
oscopies as opposed to colonoscopies performed
after positive FOBT screening in countries such as
in the UK. Added pressures of new screening pro-
grammes have involved a significant increase in
workload in the UK and throughout the
world.1 21 22
A major variable for assessing quality of all col-
onoscopy is the rate of interval cancers. For screen-
ing colonoscopy this is the most important marker
of quality. Interval cancers may occur in individuals
screened by another modality such as FOBT, there-
fore in order to differentiate interval cancers in
patients who have undergone colonoscopy and
those screened by another means, the term postco-
lonoscopy colorectal cancer (PCCRC) has been
developed.23 PCCRC rates will become the gold
standard in studies assessing surrogate quality vari-
ables such as ADR (the rate of procedures where at
least one adenoma was detected). The term
PCCRC has been used in this review where that is
the measure reported in a study but the term inter-
val cancer has been used where the data do not
specifically report postprocedural cancers.
METHODS
In this paper, we review the importance of each of
the UK KPI and QA standards and the evidence
behind them. The aim of this paper is to provide
supporting evidence for these new indicators and
standards, and to demonstrate the value and
importance of each of the measures. Each measure
is addressed in turn including caecal intubation rate
(CIR), ADR, bowel preparation, rectal retroflexion,
withdrawal time, sedation practice and comfort
levels, annual procedure volumes, polyp retrieval
rate (PRR), management of suspected malignant
lesions including tattooing of lesions, follow-up
recommendations and adherence, diagnostic biopsy
rate, PCCRC rate and adverse event rates.
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It should be borne in mind that much of the data on colonos-
copy quality have been derived from the screening setting, and
may not be automatically transferrable to diagnostic colonoscopy.
The UK standards8 were developed by a working group where
individuals were tasked with reviewing evidence in each area and
then standards agreed by consensus of all working group stake-
holders. The balance was often struck between available evidence
and expert opinion and pragmatism. The German standards9
were also developed by a working group forming a consensus on
the standards.
It is important that a systematic approach is developed
regarding the implementation and monitoring of standards.
Endoscopy programmes and units have the responsibility for
QA and they should develop QA strategies for investigating and
monitoring potential underperformance. Graphical representa-
tion, for example in the form of funnel plots,24 allows evalu-
ation of performance around a mean and helps measure
performance where the numbers of procedures vary and where
some individuals may be performing low numbers of proce-
dures. Where performance appears to fall below agreed stan-
dards then investigation should ensure that confounders such as
case mix, age and gender of patients are taken into consider-
ation. In addition, the nature of procedures should be consid-
ered, for example, complications maybe higher where advanced
therapy is undertaken. Monitoring of quality should be a con-
tinuous process and early identification of deteriorating per-
formance prior to individuals falling below lower confidence
limits is preferable. Where true underperformance is identified,
however, strategies to address this should be put in place.
THE STANDARDS
Caecal intubation rate
CIR is the most frequently used indicator of colonoscopy
quality.25–28 It is self-evident that complete examination of the
large bowel is essential to detect abnormalities,29 30 however,
CIR varies as demonstrated in a number of studies.11 31 32
Although CRCs are more commonly found in the distal colon
(61.5%), 32.7% were found proximal to the splenic flexure,
with 15% identified in the caecum or appendix, highlighting
the need for complete examination of the colon.33 Previous
work has demonstrated higher PCCRC rates in endoscopists
with a lower CIR,34 and in colonoscopies which were incom-
plete.35 PCCRCs were more commonly identified in the right
side of the colon.35 A Canadian database analysis of 1260
PCCRCs showed that endoscopists with high caecal intubation
rates and those with higher polypectomy rates had significantly
lower rates of PCCRC during follow-up.34 On the other hand,
there is limited evidence with respect to the correlation of
caecal intubation and ADR with conflicting results reported.36 37
However, it can be speculated that lower caecal intubation rates
and/or insufficient caecal visualisation may be some of the major
reasons for the higher rate of proximal PCCRCs demonstrated
in several studies (see online supplementary table S1).
A 2011 UK audit of all colonoscopies performed in a 2 week
period demonstrated an unadjusted CIR of 92.3%, rising to
95.8% following adjustment for impassable strictures and poor
bowel preparation.10 This was a significant improvement from a
previous audit in 1999, which demonstrated a CIR of 76.9%.11
This improvement was achieved following introduction of a
national training programme and a national emphasis on
improving quality. These improvements are also demonstrated
elsewhere in the UK in both general endoscopy units and within
the Bowel Cancer Screening Programme (BCSP), with
unadjusted CIR of 92.5%38 and 95.2%,36 respectively. These
large series demonstrate that caecal intubation rates >90% can
be readily achieved. The American Society for GI Endoscopy
(ASGE)/American College of Gastroenterology (ACG) taskforce
for colonoscopy sets a similar standard for diagnostic proce-
dures.28 A CIR of 95% is recommended by the European
Society of GI Endoscopy (ESGE) and the ASGE/ACG for screen-
ing colonoscopies.28 39 Reporting of caecal intubation rates may
be presented in a non-adjusted form based upon CIR in all
patients where the intention was to reach the caecum, or be
adjusted for factors such as impassable strictures and poor
bowel preparation. Different studies adjust for different factors
and this must be borne in mind when comparing different
studies (see online supplementary table S2).31 32 40–46 It may be
assumed that in the screening setting (as opposed to the symp-
tomatic service), a lower rate of poorly prepared colons and
strictures will be found, therefore the recommended higher rate
for screening versus diagnostic colonoscopy (95% vs 90%)
seems to be justified. The European Union (EU) guidelines on
the quality of colonoscopy as part of CRC screening demand a
minimum CIR of at least 90%, and suggest a rate of 95% is
desirable.23
Regarding documentation of caecal intubation, the EU guide-
lines47 recommend ‘auditable photodocumentation of comple-
tion’, as do American guidelines,26 but reported practice varies
from 50% in the UK10 to 70%–99% in other parts of
Europe.48 49 The reliability of photodocumentation of the
caecum in demonstrating completion has been questioned with
ileal photodocumentation advocated as more accurate.50 Biopsy
of the ileum may additionally be useful in confirming comple-
tion but can be technically difficult, comes with extra costs and
has some associated risks, so it is not recommended as a stand-
ard of practice.51–53
Adenoma detection rate
Most CRCs develop through the adenoma-carcinoma sequence.54
Detection and removal of these adenomas therefore reduces CRC
risk. Screening flexible sigmoidoscopy has been repeatedly demon-
strated to reduce CRC incidence and mortality,5 so it is likely that
results can be extrapolated to colonoscopy.
The ADR is currently considered the most reliable surrogate
marker of PCCRC and is therefore widely used as a marker of
colonoscopy quality.37 A lower ADR is associated with higher
rates of PCCRC,17 as demonstrated by data from the Polish
bowel cancer screening programme and a US study. In the Polish
study, colonoscopists with an ADR <20% had a hazard ration
(HR) for PCCRC that was 10 times higher than colonoscopists
with an ADR ≥20% (absolute risk 0.011% when ADR ≥20% vs
0.115% when ADR <20%).17 An inverse relationship between
ADR and PCCRC rate (and for advanced stage cancer and
cancer mortality) has also been demonstrated in a study of over
300 000 screening, surveillance or diagnostic colonoscopies,
performed by 136 colonoscopists in the USA.18 Each 1%
increase in ADR was associated with a 3% decrease in the risk
of PCCRC. The latter study suggested that there may be no
upper cut-off limit for ADR, but elements of that study should
be considered. The study was based on a medical insurance
database (Kaiser Permanente) and included both screening and
diagnostic colonoscopies. Follow-up information from the insur-
ance database was available in only 2/3 of cases and the range of
average number of annual colonoscopies per examiner included
was wide (27–461), with those undertaking low numbers
included. This raises the question as to whether all colonos-
copies per examiner were available for the analysis, or whether
some endoscopists had also performed examinations for other
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insurance providers. It is therefore possible that the ADR in the
Kaiser-Permanente database may not completely reflect endosco-
pists’ true ADR.
Both the Polish and US paper are based upon ADR. Other
measures of adenoma detection may also be important, for
example, the rate of advanced adenoma detection (AADR, those
adenomas ≥10 mm in size, or with villous components or high-
grade dysplasia),55 as advanced adenomas may be more relevant
for cancer prevention if detected and removed. The correlation
of ADR with AADR seems to yield variable results; a US study
including 1933 colonoscopies from 14 colonoscopists showed
substantial variations in both ADR and AADR, but no correl-
ation between them.55 It may well be that a high ADR mainly
reflects a high detection rate of mainly small and potentially
innocuous adenomas, as recently shown by an analysis of a con-
tinuing ADR rise over the years within the German screening
programme.56 The role of sessile serrated polyps (SSP) as pre-
cursors for CRC is an area of growing knowledge and import-
ance and as evidence for their incidence becomes more
robust.57 In the future, it may be important to consider the
detection of SSPs as a marker of quality.
While ADR is clearly important, variations on this measure of
number of adenomas detected may also be developed to gain
further insight into colonoscopy quality. ADR reflects the find-
ings of at least one adenoma in an individual but it does not
measure the number of adenomas detected in a given individual
and it is important that all the adenomas within that individual
are found. Mean adenomas per procedure (MAP, the total
number of adenomas detected divided by the total number of
procedures) and mean adenomas per positive procedures (MAP
+, the total number of adenomas detected divided by the
number of procedures with at least one adenoma detected) were
calculated for 36 000 colonoscopies performed by 177 colonos-
copists within the BCSP36 and demonstrated that some endosco-
pists detect more adenomas on average per procedure. These
quality measures may be a better representation of the perform-
ance of an individual in detecting adenomas and may be valu-
able if used as a feedback measure to allow endoscopists to
evaluate their own practice, however, clear correlation with
PCCRC rates are not yet available.
One drawback of measuring ADR is that it is dependent on
obtaining histology results following the procedure. This requires
interrogation of pathology databases to obtain polyp histology,
which can be time consuming. The polyp detection rate (PDR) is
often simpler to obtain as most electronic endoscopy reporting
software calculates it automatically. The relationship between the
ADR and PDR has been studied both in the UK and the USA, in
screening and symptomatic populations,58–60 and PDR has been
demonstrated to reliably estimate the ADR. ADR is the key per-
formance measure but where it can be demonstrated that a ratio
between an endoscopist’s PDR and ADR has been developed and
validated, then PDR may be an acceptable marker, with ongoing
review of the validity of PDR to represent ADR required.
However, it should be noted that PDR can be manipulated by
endoscopists more easily than ADR. Polypectomy rate may be
more reliable than PDR and less susceptible to gaming, and
higher polypectomy rates have been shown to correlate with
lower proximal PCCRC rates.34
ADR varies between observers, centres, cohorts of patients
and even within procedures on the same person. One systematic
review looked at six studies in which participants underwent
tandem (same day) colonoscopies.61 Miss rates for all polyps
and adenomas were 21% and 22%, respectively. A recent UK
study demonstrated wide variation in ADR with a global ADR
of 15.9%,24 although this study included patients of all ages
and only those colonoscoped for symptoms (most commonly
diarrhoea, iron deficiency anaemia and rectal bleeding). An
overview of studies focusing on the factors influencing ADR is
shown in online supplementary table S3.40 43 62–68
ADR measurements and comparisons are most relevant in
screening populations, where the reason for the procedure is
consistent and allows for the age of the screening population
and the screening modality used. It should be remembered that
expected ADR will differ between primary colonoscopy screen-
ing, colonoscopy after positive FOBTor faecal immunochemical
test (FIT) and colonoscopy within the symptomatic population.
ADR may vary for other indications with an overview given in
online supplementary table S4.69–81 It is important that these
are considered when setting a standard.
Many methods to attempt to improve ADR have been devel-
oped. These include training, endoscopic devices, medication,
position change and non-procedural aspects such as scheduling.
Detailed discussion of these measures is beyond the scope of
this review paper, however, we have provided a brief summary
of these methods.
Training: A randomised controlled trial (RCT) in Poland
revealed that dedicated training of screening centre leaders has
led to a sustained effect on colonoscopy performance among
leaders themselves and members of the unit as measured by
ADR, proximal ADR and non-polypoid lesion detection rate.82
Colonoscope factors (high definition colonoscopes, image pro-
cessing): The use of high definition colonoscopes does not seem to
result in increased ADR.83–89 One cohort study demonstrated an
increase in the number of non-flat polyps >6 mm in size when
high definition colonoscopes were used.84 Another study sug-
gested a 4.5% increase in ADR, but this retrospective review did
not adjust for confounding factors.90 Image processing (‘virtual
chromoendoscopy’, where narrow spectra of light are isolated to
enhance mucosal visualisation, or postcapture treatment of the
image) is incorporated in modern endoscopes such as narrow
band imaging (NBI)91–96 or Fujinon intelligent chromoendo-
scopy,94 or both,97 or autofluorescence imaging (AFI). Some
smaller studies have reported positive results,98 99 but these find-
ings were not confirmed by others,100 and a Cochrane review of
NBI found no evidence for an improvement in ADR over standard
endoscopy.93 For AFI, no large RCTs are yet available. Widening
and altering the angle of view has been studied. No improvement
was seen with moderate increases from 140° to 170°, but may be
demonstrated with colonoscopes with forward plus side viewing
optics. Retroflexion of the scope in the colonic lumen, mostly in
the proximal colon, increased ADR or decreased adenoma miss
rate by 2%–4.5% in most,101–103 but not all, studies.104 It is not
superior to tandem examination of the right colon,105 106 which
may be an alternative to be discussed.
Chromoendoscopy: Whether, as stated in the most recent and
largest meta-analysis,94 conventional chromoendoscopy really
has a positive effect on ADR remains doubtful, since this mostly
refers to small adenomas, and two of the nine studies analysed
were in the setting of IBD. Adding stains to colon preparation
fluids, or the administration of oral methylene blue tablets is
currently under investigation.107
Antispasmodics: Antispasmodic medications such as hyoscine
butylbromide and glucagon have been used to improve mucosal
views during colonoscopy by reducing the spasm of the colon.
They have been shown to improve ease of insertion108 and ileal
intubation rates.109 110 However, in terms of ADR, a consistent
increase when antispasmodics are used has not been demon-
strated in three meta-analyses.111–113
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Position change: Changing patient position seems to slightly
increase ADR,114 especially if colonoscopy is difficult115 116;
however again, results vary, with one recent randomised trial
suggesting no improvement,117 one suggesting an improvement
in ADR distal to the hepatic flexure118 and another suggesting
that examining the right side of the colon in the left lateral pos-
ition significantly improved ADR in the right colon.119
Mechanical methods: Methods such as the use of transparent
caps or a balloon around the endoscope tip have been tested in
numerous trials. Simple short (3–4 mm) caps at the colonoscope
tip were not shown to increase ADR as demonstrated in all but
one of six meta-analyses.94 120–123 A Cochrane review con-
cluded that while PDRs were increased with cap usage, there
was not enough evidence for an increase in ADR.121 Newer and
longer caps with side flanges (such as the Endocuff, ARC
Medical) increased ADR in two subsequent studies from the
same group124 125; however, an RCT has shown an increase in
the number of adenomas detected, but not in the overall ADR
or MAP.126 A transparent balloon around the colonoscope tip
(NaviAid G-EYE) reduced adenoma miss rate in a small tandem
study (n=126).127 128 The so-called third eye endoscope (retro-
grade view via a small ‘baby’ endoscope introduced through the
working channel) also increased ADR in a back-to-back
study,129–131 but is not in common usage.
Scheduling: Some studies suggest ADR is higher in morning
procedures than in afternoon colonoscopies,132–134 but this is
not backed up by other studies.135–137 No variation between
weekdays is demonstrated.138 In part, this is likely partially
related to the bowel preparation quality.139
Bowel preparation
Good quality bowel preparation is required in order to perform
high quality colonoscopy. Poor preparation has been associated
with incomplete tests,140 prolonged procedure time141 and with
reduced yield.142 Evidence in the UK from the national colonos-
copy audit10 showed that 22% of failed colonoscopies were due
to poor bowel preparation. While no significant difference in
large polyps (those >9 mm in size) and cancer detection has
been demonstrated related to bowel preparation, a significant
difference in detection of smaller polyps and flat lesions has
been demonstrated.143 PCCRC rates have been suggested to be
higher in those with inadequate bowel preparation,144 although
this may be multifactorial.
A number of different scoring systems for bowel preparation
are used making comparison difficult. At least five validated bowel
preparation scales exist128 145–148; all involve relatively complex
scoring systems and not all are in common usage. The UK BCSP
uses a 4-point scale: excellent, adequate, complete despite poor
preparation or failed due to poor preparation.149 The ASGE
guidelines do not suggest a preferred system for grading bowel
preparation, and the ESGE guidance for screening colonoscopy
does not recommend a specific system, but suggests that one
system should be used across all providers in order to standardise
reporting.39 It is also important to be clear at what point a score is
given. Ideally, it should be given following attempts to clean the
colon with washing and suction via the colonoscope.
Although scales have a number of levels, the only consistent
differences found in diagnostic rates were between preparation
rated as good or poor. Little additional benefit of multiple
point scales were found with no additional ADR differences
between excellent, good and moderate bowel preparation
scores.62 66 141 150 151 The most widely used scale, the Boston
Bowel Preparation Scale,147 152 demonstrated a correlation with
ADR where preparation was rated as perfect,153 although this
was not confirmed in another recent study.154 No studies dir-
ectly correlating preparation with PCCRC are available.
Despite the above limitations of scoring systems, it is self-
evident that optimal bowel preparation contributes to the
success of colonoscopy. Repeat procedures involve the waste of
clinical resources as well as increasing risk and inconvenience to
patients. The optimum bowel cleansing preparation should be
effective, tolerable for the patient and be safe, without causing
excessive shifts in electrolytes or water, and not affecting patient
concomitant medication. It should also be safe for people with
comorbidities. Multiple different regimens exist, with varying
timings, volumes and preparation constituents. The lowest
volume (and therefore often better tolerated) preparations
contain sodium phosphate, but can cause electrolyte distur-
bances and as such are not suitable for patients with comorbid-
ities. Fewer side effects are caused by polyethylene glycol (PEG)
preparations, but large volumes (up to 4 L) are required, making
the preparation less tolerable for patients. Different bowel prep-
aration methods are reviewed in a recent American consensus
document.155 Furthermore, the type and timing the of the
bowel cleansing agent is an important contributor to the quality
of the bowel preparation; however, given the lack of evidence of
one superior agent,39 units should select their preferred agent
based on local experience and any existing guidance from
gastroenterology bodies (such as the BSG guidance on bowel
preparation).156
An overview of the studies examining the correlation of bowel
cleanliness and colonoscopy quality parameters is given in online
supplementary table S5.11 31 62 66 73 141 147 150 151 153 157 158
Rectal examination and rectal retroflexion
Digital rectal examination (DRE) is recommended as a standard
part of endoscopic examination of the lower GI tract. It allows
examination of the anal canal and lower rectum for pathology,
as well as preparing the anal canal for the insertion of the
scope.159 Anal pain or sphincter spasm may occasionally mean
that it is difficult to perform a DRE; this may lead to consider-
ation of the use of topical anaesthesia and a narrow scope. A
comparison of DRE and rectal retroflexion showed that DRE
was sensitive for detection of abnormalities in the lower rectum
and upper anal canal that were subsequently demonstrated on
retroflexion of the endoscope,160 therefore, it should be rou-
tinely undertaken.
Retroflexion of the colonoscope in the rectum has long been
recommended as a technique to allow adequate visualisation of
the lower rectum and upper anal canal.159 A number of studies
have demonstrated increased detection of pathology by using
retroflexion after standard views of the rectum have been
obtained. Older studies of variable size (from n=75 to 1502,
total 3600 patients), showed an increased detection rate of
between 0.3% and 2% for adenomas.161–164 Serious rectal injur-
ies related to retroflexion leading to haemorrhage and perfor-
ation have infrequently been reported in the literature, mostly as
case reports.89 165–169 One large study of nearly 40 000 colon-
oscopies addressed this issue.168 With four rectal perforations in
the study group they estimate the risk to be 0.01%. Of these,
three were successfully managed conservatively and one
required surgical intervention. The risks and benefits of rectal
retroflexion should be carefully considered. While the technique
leads to an increased yield, it is not without risk. Therefore, it is
essential that careful attention is paid to good technique and if
resistance is encountered then the endoscopist should carefully
consider the reasons for this and have a low threshold for dis-
continuing the retroflexion. If retroflexion is aborted then
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careful antegrade inspection should be performed down to the
dentate line.
Withdrawal time
Most mucosal inspection takes place during withdrawal of the
endoscope from the caecum to the rectum and there is an
association between ADR and colonoscopy withdrawal time
(CWT)—that is, the length of time taken to remove the colono-
scope once the caecum or terminal ileum has been reached. The
CWT is calculated for each colonoscopist using cases where the
investigation was normal (in order to remove the time taken to
undertake therapy) then comparing it with ADR in all cases.
Initial work demonstrated that a CWTof >6 min was associated
with higher ADR,170 and more recently longer times of 7 or
8 min have been advocated.171 172 In a review of over 30 000
colonoscopies performed in an FOBT-positive screening popula-
tion in the UK, a CWT of up to 11 min was associated with a
higher ADR with no additional benefit beyond 11 min (ADR
43% with withdrawal 6 min or less, and 46.5% if >10 min).173
The relationship between CWT and ADR is likely to be
complex, as not all studies support the increasing ADR with
lengthening CWT.174 175 Multiple factors are likely to be
responsible for the superior ADR seen with longer CWT, such
as time being taken to fully clean and inspect all folds and flex-
ures,176 suction pools of liquid and employ position changes144
in order to optimise mucosal views. It should be noted that in at
least some of the publications the analysis was retrospective.
Prospective studies may allow for calculation of withdrawal time
in all cases by stopping the clock for polypectomy, biopsy and
other therapy.177 Increasing CWT has led to conflicting results
with regard to an increase in ADR.171 175 A study in Berlin
showed no relation between withdrawal time and ADR, but the
range of CWT (6–11 min) was already above the 6 min pro-
posed.62 Other analyses from Norway and England showed
that, using different cut-offs, longer withdrawal times led to
higher ADR.67 173 174 To recommend a specific cut-off such as
6 min is therefore only partially based on good scientific evi-
dence. It may be for this reason that the recent EU guidelines
have not published a specific withdrawal time recommenda-
tion.23 The important issue remains that adequate time is taken
for mucosal visualisation. It is unlikely that this can be achieved
in <6 min, and will sometimes take considerably longer particu-
larly if adequate mucosal views are difficult to achieve for
example, with residual colonic fluid. CWT is a surrogate marker
for ADR which, as has been outlined, is a surrogate marker for
PCCRC; therefore, it is the effect of CWTon ADR that is more
important than the CWT itself. An overview of the relevant
studies is given in online supplementary table S6.62 67 170–182
Sedation practice and comfort levels
Sedation practice varies across centres and countries. The US
and Australian practice tends towards deeper sedation (often
using propofol), whereas across Europe, Asia and Africa sed-
ation practice varies widely.183 In the UK, the majority of colon-
oscopies are performed under conscious sedation (89%), with
10% unsedated, and <1% under propofol or general anaesthe-
sia.10 In the UK, propofol sedation may only be administered by
an anaesthetist184 and these logistics may limit its use.
Elsewhere, propofol may be administered by the endoscopist, or
by an anaesthetic technician. In Germany, a large study of
almost 10 000 cases demonstrated low complication rates of
propofol-supported colonoscopy (0.03% mask ventilation due
to apnoea, 0.39% minor hypoxaemia (oxygen saturation
<90%), 0.07% bradycardia, 0.24% hypotension, 0.03%
perforation and 0.12% bleeding) and as such was felt to be safe
and cost-effective.185 However, a US cohort study demonstrated
overall increased risk of complications after colonoscopy when
anaesthesia was used, specifically with increased risk of perfor-
ation, bleeding, abdominal pain and complications of anaesthe-
sia.186 Safety recommendations for sedation dosages exist in
some countries,184 187 and the ESGE have produced a guideline
on the use of propofol.188
The approach to sedation may have a strong cultural basis
and maybe related to both patients’ expectation and clinicians’
usual practice. In some countries including Norway, unsedated
colonoscopy is the practice in selected centres for >50% of
cases. This can be achieved by good training and is well
accepted by clinicians and patients.189
Sedation practice should be considered alongside comfort, as
reduced sedation levels should not be at the expense of patient
experience. Comfort levels are affected by many factors includ-
ing technique and some evidence suggests that endoscopists per-
forming better on other KPI also provide a more comfortable
patient experience with less sedation.190 A national audit10
demonstrated that moderate or severe discomfort was experi-
enced by approximately 10% of 20 000 cases recorded. Factors
known to influence patient comfort include191 diverticular
disease; prior hysterectomy; when colonoscopy was preceded by
gastroscopy; female sex; anxiety; irritable bowel and where dis-
comfort was anticipated.
Several systems for scoring patient comfort exist, such as the
Gloucester nurse-reported 5-point scale,190 which combines fea-
tures of pain, frequency of pain and distress. Patient-reported
comfort scores use either 4-point Likert scales or 100 mm visual
analogue scales in lightly or unsedated patients.191 Validation of
scores is variable. One well-validated score exists: the Nurse
Assessed Patient Comfort Score, an international study192 in
which 300 patients undergoing colonoscopy and their endos-
copy nurses rated comfort levels. Even in this validated scoring
system, there was discrepancy between the patient-reported
levels of comfort and the clinician-reported levels, with lower
levels of comfort reported by patients. This has been demon-
strated in other studies,193 and as yet, no patient-derived, vali-
dated measures of patient experience of endoscopy exist. It is
becoming increasingly recognised that patient experience needs
to be optimised primarily to make the procedures tolerable for
patients, but also to ensure that procedures are complete, and to
optimise attendance for screening and surveillance proce-
dures.194–196 It should be mentioned that data on the influence
of sedation on ADR are not homogeneous, but most to date do
not show any correlation.197–200
The method used to distend the colon may influence patient
comfort during and after colonoscopy. Use of CO2 to insufflate
the colon has been studied extensively and repeatedly demon-
strated to improve patient comfort.39 There are few subjects
researched in endoscopy research where agreement is repeatedly
reached in all randomised trials regardless of country and set-
tings,201 202 but the method used to distend the bowel is one
such subject. The main effect is on abdominal pain experienced
on the day of colonoscopy; this is summarised in three
meta-analyses.203–205 Possible restrictions of CO2 use in patients
with chronic obstructive pulmonary disease (COPD) are not
well studied, and capnographic measurements in patients
without COPD did not show significant CO2 increases.
206–208 A
Japanese study on colorectal endoscopic submucosal dissection
(ESD) in 77 patients with COPD could not detect any differ-
ences versus controls.209 Water-aided colonoscopy (either with
water immersion or water exchange) has also been demonstrated
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to significantly reduce pain levels when compared with air
insufflation.210
Number of colonoscopies performed per year
Competency may be affected by the learning curve of colonos-
copy, ongoing number of procedures and lifetime experience.
There is considerably more literature on acquisition of compe-
tency and the learning curve than on minimal numbers for
established practitioners. The most usually studied marker of
trainee competency is CIR. In the UK, 200 colonoscopies are
currently required before provisional competency can be
assessed and 300 procedures for full competency,211 compared
with 140 for colorectal surgery and gastroenterology trainees in
the USA.212 A recent study213 demonstrated that competency
(based on a CIR of 90%) was reached by 233 procedures. Other
studies suggest similar procedure numbers required to reach
competency, with figures between 150 and 600 reported214–222;
the data are summarised in a recent review.221 A study from
Harvard showed ADR increases between 50 and 100 colonos-
copies, with no further rise thereafter.180 Similarly, another
study observing 11 fellows demonstrated increases in CIR and a
decrease of examination times between years 1 and 3, but no
change in ADR between years of training.220 It could be specu-
lated that endoscopists in training may be more attentive,223
with possibly a shorter learning curve for adenoma detection. In
a small study in the Netherlands, it was demonstrated that ADR
during training varied widely and correlated to ADR when the
individual became a consultant.224
Maintaining competence requires ongoing experience, but is
much less well studied. It has been suggested that at least 100
procedures per year is the minimum required,155 225 with some
suggesting an even higher volume of 200–300 may be neces-
sary.225 Other markers of competence such as ADR do not
appear to correlate well with procedural numbers.62 In general,
training studies mostly use CIR, however, studies on mainten-
ance of competence have explored ADR.
It is likely that prior experience and annual case volume may
be complementary at least with regard to ADR as a quality par-
ameter. A US study showed that for endoscopists with experi-
ence of up to 5 years, case volume was correlated with ADR
(92.5% for >200 vs 88.5% for <200 annual colonoscopies),
while this effect could not be shown in endoscopists with longer
colonoscopy practice and experience.225 Another study showed
the highest ADR in the middle groups of case number quintiles
as compared with colleagues with very few or many colonos-
copies.226 A study from Berlin showed no influence of case
volume on ADR.62 With regard to colonoscopy completeness,
online supplementary table S3 shows that results vary with case
volume demonstrating no,32 a positive,46 or even a negative
influence.43 In one Canadian study, case volume was correlated
with complication rates,16 which were increased in physicians
with very low case volumes.
The current EU guidelines on quality of CRC screening set the
cut-off for annual colonoscopy volume at 300.23 However, this
number can be debated with differing programmes proposing dif-
ferent levels. The correlation of case numbers and complication
rates stems from two Canadian studies16 227; one was a databank
analysis of 97 091 outpatient colonoscopies from several
Canadian provinces, which did not distinguish between diagnos-
tic and therapeutic colonoscopy for which bleeding and perfor-
ation rates may be quite different.16 The second study was a
retrospective data analysis of 24 509 examinations including
13% undergoing sigmoidoscopy. Endoscopists with annual case
volume <200 procedures had twice the complication rate. This
study did not include a multivariate analysis.227 Agreement on
the exact minimal numbers per year can be debated and in the
UK a minimum of 100 procedures per annum has been agreed.
Polyp removal, retrieval and histological analysis
After a polyp has been removed, it is currently necessary to
retrieve it for histological assessment. Polyps ≥1 cm diameter have
an increased probability of advanced features (high-grade dyspla-
sia, villous components or cancer).228 Polyps <1 cm less fre-
quently (but still potentially)54 contain these features, and do still
require retrieval. Histology of polyps is used to calculate surveil-
lance intervals based on adenoma numbers229–231 and in some
countries numbers of serrated polyps. Polyp retrieval is also con-
sidered a reflection of the technical skill and application of the
colonoscopist. Studies have shown no difference in the success
rates of methods of polyp retrieval (eg, suction,232 Roth nets233)
with some techniques limited by polyp size. The recommended
PRRs are ≥90% in the UK and ≥95% in the USA.26 234 235
In the future, endoscopic visual assessment of polyps in vivo
using enhanced imaging modalities may allow accurate optical
identification of adenomatous polyps, which then will not
require histological review, reducing histopathology work-
load.236 This so-called Detect InSpect Characterise Resect And
Discard (DISCARD) strategy—mainly for polyps ≤5 mm—has
been summarised in multiple reviews and meta-analyses,237–241
and in a recent ASGE recommendation update.242 This review
shows that almost all endoscopic techniques seem to reach high
accuracy rates in endoscopic polyp differential diagnosis, mainly
based on studies from expert centres.86 243 244 The Preservation
and Incorporation of Valuable Endoscopic Innovations (PIVI)
statement issued by the ASGE has issued advice on acceptable
performance thresholds for real-time endoscopic assessment of
diminutive polyps required before optical diagnosis should be
recommended for routine clinical practice.245 The PIVI state-
ment advises that optical diagnosis can be used for diminutive
(1–5 mm) and histological diagnosis for small (6–9 mm) polyps
and those summated results used to determine surveillance.
Under routine conditions in non-expert centres, such a differen-
tial diagnosis does not seem to work,204 244 246 247 as recently
confirmed in a large multicentre UK trial, which indicated that a
DISCARD policy was not yet generalisable to routine clinical
settings.248 A further difficulty for polyp differential diagnosis is
the increasing focus on sessile serrated adenomas (SSA).249–251
Their endoscopic detection and histopathological confirmation
varies considerably, particularly with regard to the differential
between SSA and hyperplastic polyps,252 253 with substantial
rates of reclassification of hyperplastic polyps as SSA on second
opinion.249 254–256 There is also substantial interobserver vari-
ability in the histological diagnosis.249 257 258 New endoscopic
assessments259 and classifications are underway.260 Given this
evidence, further work is required to define the role of a
DISCARD strategy in routine clinical practice.
Completeness of resection is another potential quality indica-
tor that would require both endoscopic and histopathological
data. Since several factors impede a reliable histological assess-
ment (piecemeal resection by forceps or snare, damage from
thermal therapy), this has not been introduced into routine
quality parameters. Endoscopic visual assessment of complete-
ness of resection is often said to need improvement.261
Management of suspected malignant lesions and those not
suitable for endoscopic resection
As polyps increase in size the risk that they harbour cancer
increases, with malignant change found in 2.2%, 18.7% and
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42.7% of polyps of size 6–15 mm, 16–25 mm and 26–35 mm,
respectively.262 Submucosal invasion was found in 7.8% of
polyps ≥2 cm in size on a large meta-analysis,263 and higher
rates of submucosal invasion are found in laterally spreading
tumours, particularly the non-granular type.264 Current UK and
American guidelines suggest all polyps ≥2 cm in size should
have a tattoo placed nearby to mark their location. Lesions
<2 cm in diameter should be carefully inspected, and poten-
tially have their site marked if they have high-risk features.265
This also applies to small, subcentimetre polyps that, as
described recently, may also have distinctive malignant features.
In such instances, polyps should be resected with care, ensuring
completeness using very careful injection technique.266
The decision as to whether a lesion is amenable to resection
may be influenced by physician interpretation and experi-
ence.267 Polyps may appear unresectable due to features suggest-
ing malignancy or technical factors impeding polypectomy such
as location, size and polyp characteristics. Different endoscopists
with different skill levels may have different views. Assessment
of malignancy is difficult with many endoscopic studies using
different classification systems.103 268–270 There are two major
polyp classification systems. The Paris classification268 is based
upon polyp shape and relationship to the surrounding mucosa
and reflects the morphology of lesions. The Kudo classifica-
tion269 based on the pit pattern on the surface of the polyp is
very important in indication of malignancy. The Japanese litera-
ture mostly involves the combined assessment of ‘mucosal’
(high-grade dysplastic) and submucosally invasive cancers. There
are limited Western data. A large Australian polyp study
(n=479) identified the following univariate risk factors for inva-
sive cancer: Paris classification 0–IIa+IIc, morphology (non-
granular surface) and Kudo pit pattern type V.271 In this study,
31.8% of the 22 Paris type IIc or IIa+IIc lesions, 15.3% of the
98 non-granular lesions and 56% of the 25 Kudo type V polyps
had malignant histology equivalent to invasive cancer; and
should serve as a reminder to consider invasive cancer within
these lesions.271 Although not done in this study, Kudo type V
is ideally substratified to Vn (may be high-grade dysplasia only)
and Vi which is more closely correlated to submucosal invasive
disease. The recently developed National Institute for Health
and Care Excellence classification, which uses enhanced optical
imaging techniques to evaluate lesions, showed high levels of
accuracy in predicting submucosal invasion.272 Studies to date
have involved image analysis and not yet in vivo endoscopic
diagnosis. As such, making a prediction about the presence of
invasive malignancy in polyps should be based on an assessment
of both polyp morphology (such as the Paris classification) as
well as microscopic features (such as pit pattern or NBI vascular
pattern). The ‘non-lifting sign’ may indicate the possibility of
malignancy and submucosal invasion,273 274 but not reliably so.
It is important to differentiate a true non-lifting sign in a polyp
where removal has not been previously attempted as compared
with non-lifting related to scaring from previous attempted
polypectomy. There may be other technical reasons making
benign polyps difficult to resect and the ‘non-lifting sign’273 275
may again be important,273 274 indicating expected technical dif-
ficulties during resection.271 The differentiation between tech-
nically and clinically meaningful endoscopic resectability of a
given colonic polyp therefore rests on the combined macro-
scopic and possibly histological assessment but evidence varies.
Assessment of resectability correlates with the experience of the
examiner. It has been shown that some polyps deemed not to be
resectable by one endoscopist may be resected when referred to
expert centres,276–281 so automatic referral of these patients to
surgery does not seem to be justified. In these expert centres,
around 10% of patients ultimately undergo surgery for different
reasons.282 283 Thus, patients with complex polyps should be
assessed in centres with full surgical back up, where a minimally
invasive endoscopic resection may still be possible. Use of
complex polyp multidisciplinary team meetings for such polyps
may be beneficial when deciding upon their management.267
A complex question relates to which resection technique
should be applied to lesions where there is a suspicion of malig-
nancy and this is also limited by difficulty in endoscopic diagno-
sis of malignancy. The techniques most widely used are
endoscopic mucosal resection (EMR) or en bloc endscopic sub-
mucosal dissection (ESD). Detailed discussion is beyond the
scope of this review; however, recent studies show an overall
success rate of EMR of over 90%,271 284 but at the cost of
repeated colonoscopies for treating remnant or recurrent
lesions. ESD on the other hand appears to be complex and asso-
ciated with a higher complication rate, with excellent midterm
results in studies from the Far East.285–298 The main limitations
of these data are that simple adenomas, adenomas with high-
grade dysplasia (often referred to as mucosal cancers) and inva-
sive cancers are mixed together. Separate results for submucosal
cancers are only rarely shown in detail, and if so, at least in
Western studies, a high rate of secondary surgery is
reported.289 290 Long-term outcomes of patients undergoing
endoscopic management of submucosal invasive CRCs are now
beginning to emerge. In those with low risk features (negative
vertical resection margins, well or moderately differentiated
adenocarcinoma, lack of lymphovascular invasion and an inva-
sion depth of <1000 μm), the recurrence rate at 5 years was
0.8% vs 6.6% (p<0.05) in those who lacked these features.299
It has also been shown that in those with high risk features, the
risk of local recurrence was significantly higher in submucosal
rectal cancers than in submucosal colon cancers.300 It is also
now known that the risk of lymph node metastasis of T1
cancers is around 10%,301 and can be predicted by the presence
of unfavourable histological findings (lymphatic invasion,
budding, submucosal invasion ≥1 mm and poor histological dif-
ferentiation).302 Data such as these will inform decision-making
at polyp multidisciplinary team meetings, particularly decisions
regarding additional surgery.
Tattooing of the mucosa adjacent to all suspected malignant
lesions and resection sites of polyps ≥2 cm (other than those in
the lower rectum and those proximal to the ileocaecal valve
where landmarks are clear) allows optimal localisation of lesions
for further endoscopic assessment or surgical resection303 and
promotes accurate endoscopic surveillance postpolypectomy.
This technique was first described in the 1970s.304 To minimise
the risk of injecting the marker through the mucosal wall into
the peritoneum and causing a localised inflammatory reac-
tion,305 306 a two-step method where a bleb of saline is raised
just below the mucosal layer and then indelible marker injected
into this fluid should be used.307 There is however a caveat;
regular tattooing of all lesions deemed to be unresectable may
make subsequent endoscopic resection (as already discussed in
this section) more difficult because of scarring and fibrosis at the
base of the lesion, so tattoos should not be placed too close to
the lesion.
Follow-up recommendations and adherence
A number of detailed recommendations for follow-up colonos-
copy after polypectomy of adenomas exist. These are based
upon the number, size and histology of polyps.229 230 308 From
a QA standpoint, adherence to surveillance intervals should be
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considered among important quality indicators; a high ADR can
be neutralised by poor quality polypectomy and also by poor
adherence to follow-up guidelines. This may be also the reason
why some studies from Norway and France have not shown any
positive effect of polypectomy on decreasing CRC rates. In
Norway, follow-up recommendations were 10 years for
advanced adenomas, and perhaps therefore, these patients had a
higher CRC risk than the normal population; on the other
hand, there was no follow-up recommended in smaller (non-
advanced) adenomas, and paradoxically, these patients had a
lower CRC risk.309 A French follow-up study after polypectomy
within the national screening programme (FOBT followed by
colonoscopy if positive) also showed an increased mortality
from CRC (standardised incidence ratio 1.26), but this corre-
lated with adherence to follow-up examinations. Patients with
follow-up compliance had a lower risk (1.10 vs 4.26).310
Whether follow-up should be more strictly adhered to or inten-
sified in certain patients with certain adenomas is a very import-
ant clinical question and several studies of the value and interval
of surveillance are underway.311–313
Diagnostic biopsies for unexplained diarrhoea
A macroscopically normal examination does not exclude all
causes of diarrhoea. A study of 809 cases found clinically rele-
vant abnormalities in 15% of cases.314 In this study, the most
common diagnosis was microscopic colitis (80 cases, 10%),
including lymphocytic and collagenous colitis.315 The European
Microscopic Colitis Group316 reports the incidence as similar to
that of classical IBD.
Some studies, however, suggest that the majority of causes of
diarrhoea can be identified within the range of a flexible sig-
moidoscopy.314 As such, rectal biopsies alone may be sufficient
to diagnose or exclude microscopic colitis, particularly in
patients under 45 years, where the diagnostic yield of flexible
sigmoidoscopy is not significantly different to that of colonos-
copy.317 Other data exist suggesting that changes in the large
bowel mucosa may be patchy, and as such, left-sided and right-
sided colonic biopsies should be taken for diagnosis.318–321
However, the cost-effectiveness of this policy has been ques-
tioned.322 Local policies on biopsy for unexplained diarrhoea
should be developed.
Postcolonoscopy colorectal cancer rate
As previously stated, PCCRC, also called colonoscopy interval
cancer, is a CRC diagnosed after a colorectal screening examin-
ation or test in which no cancer is detected, and before the date
of the next recommended examination.323 PCCRCs may repre-
sent a missed cancer, a cancer arising in a missed or incom-
pletely treated adenoma, or a cancer that started to develop
after the colonoscopy. PCCRCs are potentially the most import-
ant markers of colonoscopy quality but due to their relative
rarity and the time delay to diagnosis, PCCRC rates are difficult
to measure and interpret.324
Online supplementary table S1 provides an overview of
studies looking into PCCRCs and explores influencing
factors.17 18 29 30 325–338 It should be noted that almost all these
studies are based on retrospective analyses of large databases
and the quality of these may vary. A recent study with careful
investigation of each case showed that in an institutional data-
base including 43 661 colonoscopies, 21 of 45 cancers reported
as interval cancers database were found to be incorrectly
recorded due to administrative errors.339
Several studies have described PCCRC rates, with wide vari-
ation from 0% to 9% (online supplementary table S1).34 Study
design and definition of PCCRC in terms of time intervals
varies between studies, making comparison difficult.340 One
study demonstrated an overall PCCRC rate of 8.5% (in patients
diagnosed with CRC who underwent colonoscopy within
3 years prior to cancer diagnosis), but also suggested that these
rates have been declining with time, from 10.6% in 2001 to
6.8% in 2008.324 More recently, it has been demonstrated that
a higher FIT haemoglobin concentrations is an independent pre-
dictor of PCCRC,341 and with increasing use of FIT may be an
area for future study.
PCCRCs may be related to endoscopist performance, for
example, with poor mucosal inspection or incomplete polypect-
omy, or related to biological factors of the patient, such as aggres-
sive pathology of colorectal lesions. Morphology may be
important with the detection of subtle, flat, depressed and ser-
rated lesions highly variable among endoscopists, particularly in
the proximal colon.342 343 Clearly there is overlap, but quality of
colonoscopy is strongly endoscopist dependent.340 Back-to-back
colonoscopy studies demonstrate that significant lesions may be
missed12 61 and colonoscopists with high ADR and high poly-
pectomy rates provide increased protection for proximal cancers
compared with those with lower polypectomy rates.34
Polypectomy technique also influences PCCRC, with incom-
plete polypectomy contributing to later cancers.332 Pooled
North American postpolypectomy studies334 demonstrate
missed cancer contributing 52% to the PCCRC rate, with 19%
possibly due to incomplete polyp resection. A further study329
found 27% of PCCRCs developed in the same segment as a pre-
vious polypectomy suggesting that incomplete treatment may
have been a contributory factor.
PCCRCs are hugely important and reducing them is a crucial
element of any colonoscopy programme. However, given their
relative rarity, difficulties in data acquisition including data pro-
tection and the long intervals before they develop mean that
their role as markers of quality is limited and currently surrogate
markers will continue to be needed.
Adverse events
Colonoscopy is an invasive procedure, which carries a risk of
bleeding, perforation and even death. Although the risk is small
with diagnostic colonoscopy, it increases markedly when thera-
peutic procedures such as polypectomy are performed. There have
been several reviews on colonoscopy complications, most recently
by ASGE344 as well as a review specifically focusing on complica-
tions of screening colonoscopy.345 Online supplementary table S7
provides an overview of the most relevant large
series.11 16 48 151 227 345–353
A very important issue regarding adverse event assessment
within QA and/or benchmarking is who records which data
with which methodology over which period of time following
colonoscopy. Databases such as the German screening colonos-
copy registry underreported complications when audited along-
side a prospective study.62 Ease of collection of data varies,
depending on whether only acute complications during the pro-
cedure or on the day of the procedure, hospital stay (if any) or
all complications within a 2-week or 4-week follow-up period
are recorded. Whether and to what extent the simple linkage of
databases of hospitals, registries and insurance companies is
helpful354 is still uncertain due to variable and often insufficient
data quality.
The EU guidelines recommend three methods of QA with
regard to complications (contact with all patients at a certain
point in time after colonoscopy, review of 30-day mortality, and
review of unplanned hospital admissions within 8 days); they
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however also admit that not all national or regional databases
allow for such analyses. Therefore, the EU guidelines name
unplanned admission on the day of colonoscopy (including
reason for admission) as a KPI.23
Perforation rates
The proportion of diagnostic to therapeutic procedures per-
formed influences the overall colonoscopic perforation rate. In
four large series of 97 000–277 000 colonoscopies, overall per-
foration rates ranged from 0.03% to 0.085%.13–16 23 A recent
review of studies calculated an overall perforation rate of 0.07%
(1 in 1400).355 Studies have quoted perforation rates ranging
from 0% to 0.2% for diagnostic colonoscopy.151 356 The
English BCSP has reported a diagnostic perforation rate of 1 in
3253 (0.03%).357 The two main risk factors for postpolypect-
omy perforation are the size and proximal (caecal) location of
polyps.357 Two small prospective polypectomy series reported
perforation rates of 1 in 153 (0.65%) and 1 in 368 (0.27%),
whereas two slightly larger retrospective series reported rates of
1 in 923 (0.11%) and 1 in 1583 (0.06%).351 358–360 A recent
review of studies calculated the perforation rate in therapeutic
colonoscopy to be 0.1%.355 The English BCSP has reported a
perforation rate in polypectomy procedures of 0.09%.357 It
should be acknowledged that, particularly in the era of EMR
and ESD techniques, polypectomy perforation rates will vary
according to the size, location and complexity of polyps
removed.
Bleeding
The risk of postprocedural bleeding is very small with diagnostic
colonoscopy, but increases markedly when polypectomy is per-
formed. Bleeding rates of 0.3%–6.1% for polypectomies are
reported.151 361 The two main risk factors are the size and prox-
imal (caecal) location of polyps.357 359 Other reported risk
factors include comorbidity including cardiovascular or chronic
renal disease,362 age,361–363 anticoagulant use361 362 and endos-
copist experience.361 Studies assessing the effect of polyp
morphology are inconclusive, with some studies demonstrating
higher risks for pedunculated363 or sessile/thick-stalked
polyps,361 but others showing no effect.357 364 The recent UK
audit reported an overall bleeding rate of 0.26%,10 and a recent
large series reported a colonoscopy bleeding rate of 0.164%.16
The UK BCSP data illustrate the importance of stratifying bleed-
ing severity: in one study, the overall bleeding rate (including
many clinically insignificant bleeds) was calculated as 0.59%;
limiting the analysis to intermediate or major severity bleeds
(haemoglobin drop of 2 g, blood transfusion, admission to
intensive care, unplanned hospital admission for four or more
nights, interventional radiology or endoscopy or surgery), the
rate was 0.13%36; and limiting only to bleeding requiring trans-
fusion, the rate was 0.04%.357
Polypectomy adverse events and size of polyp
Overall, it is primarily polyp size that determines the risk of
adverse events of bleeding and perforation.357 On multivariate
analysis, the Munich Polypectomy Study (MUPS) of 2257
patients showed polyp size was the main risk factor for signifi-
cant adverse events (OR 31.01, 95% CI 7.53 to 128.1).359
Other studies have reached similar conclusions.357 361–363 365–
368 Several studies have demonstrated that the risk of polypect-
omy relates to colonic location. The MUPS reported that prox-
imal polyp location was a significant risk factor for major
complications (OR 2.40, 95% CI 1.34 to 4.28).359 A further
study of 2106 polypectomies also showed that right-colon
polypectomies had a higher tendency of developing postpoly-
pectomy syndrome and bleeding (p=0.002).369 A case control
study of 39 cases demonstrated that polyps in the right colon
had an OR of 4.67 for postpolypectomy delayed haemorrhage
(1.88–11.61, p=0.001),364 and also suggested that the caecum
seemed to be especially at high risk in univariate analysis (OR
13.82, 95% CI 2.66 to 71.73), but this could not be confirmed
in multivariate analysis due to small numbers.357
CONCLUSION
Delivery of high quality colonoscopy should be the aim of all
colonoscopists and colonoscopy programmes. It is important
that quality measures and KPI are developed for all pro-
grammes. These measures of quality should be robust370 and
evidence based and programmes should develop systems for
data collection and monitoring.371 High quality colonoscopy
should ensure low complication rates, low PCCRC rates and
should provide patients with an acceptable procedural
experience.
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